Salud financiera de hoja de balance de AmCad BioMed

Salud financiera controles de criterios 6/6

AmCad BioMed tiene un patrimonio de los accionistas total de NT$451.6M y una deuda total de NT$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son NT$481.3M y NT$29.8M respectivamente.

Información clave

Ratio deuda-patrimonio

NT$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	NT$257.10m
Patrimonio	NT$451.55m
Total pasivo	NT$29.78m
Activos totales	NT$481.33m

Actualizaciones recientes sobre salud financiera

Companies Like AmCad BioMed (GTSM:4188) Are In A Position To Invest In Growth

Apr 19

AmCad BioMed (GTSM:4188) Is In A Good Position To Deliver On Growth Plans

Jan 04

Recent updates

Companies Like AmCad BioMed (GTSM:4188) Are In A Position To Invest In Growth

Apr 19

AmCad BioMed (GTSM:4188) Is In A Good Position To Deliver On Growth Plans

Jan 04

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (NT$298.5M) de 4188 superan a sus pasivos a corto plazo (NT$21.3M).

Pasivo a largo plazo: Los activos a corto plazo de 4188 (NT$298.5M) superan a sus pasivos a largo plazo (NT$8.5M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 4188 está libre de deudas.

Reducción de la deuda: 4188 no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 4188 tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: 4188 tiene suficiente cash runway para más de 3 años si el flujo de caja libre sigue creciendo a tasas históricas de 20% cada año

Salud financiera de hoja de balance de AmCad BioMed

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Companies Like AmCad BioMed (GTSM:4188) Are In A Position To Invest In Growth

AmCad BioMed (GTSM:4188) Is In A Good Position To Deliver On Growth Plans

Recent updates

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: NT$0.19 loss per share (vs NT$0.24 loss in 2Q 2023)

AmCad BioMed Corporation Announces Change of the Corporate Governance Officer

AmCad BioMed Corporation to Report Q2, 2024 Results on Aug 08, 2024

AmCad BioMed Corporation has completed a Follow-on Equity Offering in the amount of TWD 230 million.

First quarter 2024 earnings released: NT$0.29 loss per share (vs NT$0.20 loss in 1Q 2023)

AmCad BioMed Corporation has filed a Follow-on Equity Offering in the amount of TWD 350 million.

AmCad BioMed Corporation to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: NT$0.85 loss per share (vs NT$1.01 loss in FY 2022)

AmCad BioMed Corporation, Annual General Meeting, Jun 26, 2024

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: NT$0.24 loss per share (vs NT$0.22 loss in 2Q 2022)

New minor risk - Share price stability

AmCad BioMed Corporation Announces Management Changes

AmCad Biomed Corporation Appoints Maureen Chang as Corporate Governance Officer

Less than half of directors are independent

Third quarter 2022 earnings released: NT$0.27 loss per share (vs NT$0.001 profit in 3Q 2021)

Second quarter 2022 earnings released: NT$0.22 loss per share (vs NT$0.16 loss in 2Q 2021)

First quarter 2022 earnings released: NT$0.15 loss per share (vs NT$0.21 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

AmCad BioMed Corporation Appoints Maureen Chang as Spokesperson, Financial Officer and Accounting Officer

Third quarter 2021 earnings released: EPS NT$0.001 (vs NT$0.18 loss in 3Q 2020)

AmCad BioMed Corporation Announces Receiving FDA Approval of AmCad UTdeep Learning Advanced Version

Second quarter 2021 earnings released: NT$0.16 loss per share (vs NT$0.10 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.21 loss per share (vs NT$0.30 loss in 1Q 2020)

Companies Like AmCad BioMed (GTSM:4188) Are In A Position To Invest In Growth

Full year 2020 earnings released: NT$0.67 loss per share (vs NT$0.71 loss in FY 2019)

Full year 2020 earnings released: NT$0.67 loss per share (vs NT$0.71 loss in FY 2019)

AmCad BioMed Corporation, Annual General Meeting, May 21, 2021

New 90-day low: NT$18.55

New 90-day low: NT$18.80

AmCad BioMed (GTSM:4188) Is In A Good Position To Deliver On Growth Plans

Third quarter 2020 earnings released: NT$0.19 loss per share

AmCad BioMed Corporation Announces Board Changes

AmCad BioMed Corporation Announces Resignation of Lee, Chen Chia as Chairperson, Effective November 5, 2020

New 90-day low: NT$19.45

First half earnings released

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera